Ipca Laboratories is in the process of obtaining environmental clearance for setting up a new active pharmaceutical ingredients (API) manufacturing unit at Dewas, Madhya Pradesh (MP) with an initial capital outlay of about Rs 250 crore. The company has already acquired land for the project. Currently, it produces over 80 APIs at 12 production facilities, accounting for nearly 25 percent of its turnover.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
